YEM Search

搜索结果

CLDN1

靶点ID:TCMBANKGE001023

靶点别名:CLD1; ILVASC; SEMP1

靶点描述:claudin 1

染色体:3

染色体位置:3q28

靶点类型:protein-coding

HERB_ID:-

HGNC_Link:2032

OMIM_Link:603718

Ensembl_Link:ENSG00000163347

靶点对应的植物

ID	拉丁名	药名	药用植物名	功能与主治	来源	药用部位	使用民族

TCMBANKHE000002/YEM-918	Fructus Punixae Granati\|Punica granatum L.	石榴	石榴		云南民族药物志：第五卷	Punica granatum L.	阿昌族/白族/傣族/德昂族/回族/哈尼族/景颇族/傈僳族/苗族/水族/佤族/彝族/藏族

靶点对应的化合物

化合物ID	化合物名	别名	分子式	分子质量	Smiles

TCMBANKIN036881	delphinidin	delphinidin ; delfinidin; delphinidin-3-glu-coside_qt; Anthocyanin; Delphinidin-3-monoglucoside_qt; 3-O-β-(6-O-malonyl)-D-glucopyranoside_qt	C15H11O7+	303.24 g/mol	C1=C(C=C(C(=C1O)O)O)C2=[O+]C3=CC(=CC(=C3C=C2O)O)O
TCMBANKIN057905	ferrum	iron	Fe	55.84 g/mol	[Fe]
TCMBANKIN058053	diallyl trisulfide	DSSTox_CID_25972; SCHEMBL562845; CHEMBL123040; 3-(prop-2-enyltrisulfanyl)-1-propene; Trisulfide,di-2-propen-1-yl; Prop-2-enyl-trithio prop-2-ene; 1,3-Diallyltrisulfane; DSSTox_GSID_45972; 4,5,6-Trithia-1,8-nonadiene; Allyl trisulfide, 8CI; FEMA 3265; MolPort-003-665-652; DTXSID9045972; 050D875; Allitridin; 2050-87-5; Trisulfide, di-2-propenyl (9CI); NSC651936; allitridin; diallylTrisulfide; A814621; Diallyl trisulfide, >=98% (HPLC); EINECS 218-107-8; BDBM50318454; 8008-99-9; AI3-35127; C6H10S3; RT-003641; Diallyltrisulfide; CJ-26310; diallyltrisulfane; CTK3J7216; 1,3-Diallyltrisulfane #; CCG-230978; CCRIS 3251; C-51303; KS-00000ZOW; M259; bis(prop-2-en-1-yl)trisulfane; Tox21_111500; AC1L27PI; Garlic oil; BRN 1745734; Jsp004197; FT-0626632; Diallyl trisulphide; allitridum; FT-0624607; SPECTRUM1505014; 0-01-00-00441 (Beilstein Handbook Reference); (CH2=CHCH2S)2S; DSSTox_RID_81264; UBAXRAHSPKWNCX-UHFFFAOYSA-N; Diallyl trisulfide, >=97% (HPLC); AKOS006282485; ALLYL TRISULFIDE; UNII-609MRV3T0J component UBAXRAHSPKWNCX-UHFFFAOYSA-N; 3-(allyltrisulfanyl)prop-1-ene; Q-100252; CAS-2050-87-5; DB-003624; CHEBI:78492; Dasuansu; NCGC00095290-01; Prop-2-enyl prop-2-enylthio disulfide; NCGC00095290-02; AB1006016; KB-49701; FEMA No. 3265; NSC 651936; Diprop-2-en-1-yltrisulfane; diallyl trisulfide ; 0ZO1U5A3XX; NSC-651936; BC216501; UNII-0ZO1U5A3XX; I09-0167; Trisulfide, di-2-propenyl; Diallyl trisulfide; AN-19812; Di-2-propenyl trisulfide; FCH834827; 1,3-Diallyltrisulfane; LS-2660; 3-(prop-2-enyltrisulfanyl)prop-1-ene; DSSTox_CID_25972; SCHEMBL562845; CHEMBL123040; 3-(prop-2-enyltrisulfanyl)-1-propene; Trisulfide,di-2-propen-1-yl; Prop-2-enyl-trithio prop-2-ene; 1,3-Diallyltrisulfane; DSSTox_GSID_45972; 4,5,6-Trithia-1,8-nonadiene; Allyl trisulfide, 8CI; FEMA 3265; MolPort-003-665-652; AIDS008801; DTXSID9045972; 050D875; Allitridin; 2050-87-5; 3-prop-2-enylsulfanyldisulfanylprop-1-ene; Trisulfide, di-2-propenyl (9CI); AIDS-008801; NSC651936; A814621; Diallyl trisulfide, >=98% (HPLC); EINECS 218-107-8; BDBM50318454; 8008-99-9; AI3-35127; C6H10S3; RT-003641; Diallyltrisulfide; CJ-26310; diallyltrisulfane; CTK3J7216; 1,3-Diallyltrisulfane #; CCG-230978; CCRIS 3251; C-51303; KS-00000ZOW; M259; bis(prop-2-en-1-yl)trisulfane; Tox21_111500; AC1L27PI; Garlic oil; BRN 1745734; Jsp004197; FT-0626632; Diallyl trisulphide; allitridum; FT-0624607; SPECTRUM1505014; 0-01-00-00441 (Beilstein Handbook Reference); (CH2=CHCH2S)2S; DSSTox_RID_81264; UBAXRAHSPKWNCX-UHFFFAOYSA-N; Diallyl trisulfide, >=97% (HPLC); AKOS006282485; ALLYL TRISULFIDE; UNII-609MRV3T0J component UBAXRAHSPKWNCX-UHFFFAOYSA-N; 3-(allyltrisulfanyl)prop-1-ene; Q-100252; CAS-2050-87-5; DB-003624; CHEBI:78492; Dasuansu; NCGC00095290-01; 3-allylsulfanyldisulfanylprop-1-ene; FEMA No. 3533; Prop-2-enyl prop-2-enylthio disulfide; NCGC00095290-02; AB1006016; 3-(allylthio)disulfanylprop-1-ene; KB-49701; FEMA No. 3265; NSC 651936; Diprop-2-en-1-yltrisulfane; 0ZO1U5A3XX; NSC-651936; BC216501; UNII-0ZO1U5A3XX; I09-0167; Trisulfide, di-2-propenyl; Diallyl trisulfide; AN-19812; Di-2-propenyl trisulfide; FCH834827; 1,3-Diallyltrisulfane; LS-2660; 3-(prop-2-enyltrisulfanyl)prop-1-ene; allitridin	C6H10S3	178.34	C=CCSSSCC=C
TCMBANKIN058205	trans-resveratrol	(E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; SRT501; AX8004672; DB02709; RP17549; NCGC00017352-05; NCGC00017352-13; NCGC00017352-19; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; 4CN-0696; I06-0437; 3,4',5-Trihydroxy-trans-stilbene; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; s1396; HMS1990H15; SAM001246888; CPD000058206; CU-01000001503-3; BPBio1_000479; NCGC00024003-14; (E)-5-(p-Hydroxystyryl)resorcinol; FT-0082623; Tox21_501111; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 01R360; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Tox21_303376; MLS001055357; NCGC00024003-13; GP5884; A827984; resveratrol; NCGC00017352-09; NCGC00017352-15; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; NCGC00024003-11; D0U3EP; ACN-034773; ST057251; EU-0101111; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; HY-16561; N1848; ACT09778; NCGC00017352-17; BRD-K80738081-001-09-6; KUC104385N; 3,4',5-Trihydroxy-trans-stilbene 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; LUKBXSAWLPMMSZ-OWOJBTEDSA-N; STL; MLS001424228; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzoldiol; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol; HMS1569F17; Resveratrol, Vetec(TM) reagent grade, 98%; HMS1921N04; IDI1_002152; Resvida; KB-02515; SR-01000000163-10; NCGC00017352-08; AB00052942_31; 3,5,4'-Trihydroxystilbene; trans-Stilbene-3,4',5-triol; Tox21_110257; NCGC00024003-12; trans-3,4′,5-Trihydroxystilbene; trans-3,4',5 - trihydroxystilbene; ZB000650; ZINC6787; DSSTox_RID_78898; NCGC00024003-09; 3fts; BB_NC-2570; SRT-501; ZX-AS004941; 5-[(E)-2-(4-Hydroxyphenyl)ethenyl]benzol-1,3-diol; BRD-K80738081-001-23-7; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; NSC327430; LS-2146; (E)-5-(4-Hydroxystyryl)benzene-1,3-diol; NCGC00024003-04; DSSTox_CID_11980; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol; Prestwick3_000508; trans-Resveratrol, United States Pharmacopeia (USP) Reference Standard; Resveratrol, European Pharmacopoeia (EP) Reference Standard; NCGC00015894-02; ARONIS24568; STL146386; R 5010; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; AC1L9HIC; BSPBio_003461; REGID_for_CID_445154; C14H12O3; SR-01000000163-11; 501-36-0; C03582; SRT 501; NSC 327430; NSC-327430; Spectrum5_000552; AS-12413; Trans-3,4′ NCGC00024003-06; AKOS005720936; BG01529320; BBC/741; HMS1792H15; NCGC00258925-01; TL8003323; AB00052942-29; SR-01000000163-4; SR-01000000163-16; BSPBio_000435; Opera_ID_586; NC00349; 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-; ZX-AT013797; 375823-41-9; HMS3403H15; 3,4',5-Trihydroxystilbene; HMS2232A18; KSC-10-164; AN-865; LMPK13090005; AJ-08292; OR46018; R0071; CHEMBL165; BRD-K25591257-001-01-2; Resveratrol, E-; BBL028252; NCGC00024003-05; LP01111; UNII-Q369O8926L; CCG-38874; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; MFCD00133799; 2l98; BDBM23926; SGCUT00007; GP2549; Resveratrol, trans-; CC-34242; ST2408097; MLS001076538; AK-39118; HMS1362H15; NCGC00024003-07; ABP000376; SBB055452; NCGC00017352-16; trans-3,5,4'-Trihydroxystilbene3,4',5-Stilbenetrioltrans-Resveratrol(E)-5-(p-Hydroxystyryl)resorcinol(E)-5-(4-hydroxystyryl)benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; Tox21_110257_1; BRD-K80738081-001-06-2; Resveratrol, certified reference material, TraceCERT(R); 3,4',5-Stilbenetriol; MCULE-5678456463; J10118; BSPBio_001114; HMS2052I09; Resveratrol, >=99% (HPLC); CS-1050; SCHEMBL19425; 5[(E)-2-(4-Hydroxyphenyl)-vinyl]benzene 1,3-diol; Resveratol; (E)1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; HMS3263O04; 4jaz; AB0006623; CAS-501-36-0; CCRIS 8952; MLS000069735; trans-3,4',5-trihydroxystilbene; 4qer; Tox21_201374; to_000079; SPECTRUM1502223; BC202036; API0000480; NCGC00017352-10; CHEBI:27881; NCGC00017352-24; SY014849; 3,4',5-trihydroxy-stilbene; NCGC00017352-06; PREVENTION 8 (RESVERATROL); MolPort-002-499-801; (E)-resveratrol; BCPP000091; Prestwick_619; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; SMR000058206; cid_445154; Q369O8926L; Resveratrol, analytical standard; DSSTox_GSID_31980; NCGC00017352-11; AC-727; HMS2096F17; BS0159; 5-[2-(4-hydroxyphenyl)vinyl]-1,3-benzenediol; BRD-K80738081-001-10-4; NCGC00017352-12; MLS002222231; Resveratrol, natural; Lopac0_001111; BR-39118; CJ-00111; NCGC00017352-07; DTXSID4031980; CR-003; Stilbene, 2f; NCGC00017352-18; NCGC00024003-10; SC-11924; SR-01000000163-3; MLS002207121; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; NCGC00024003-00; HMS3649A20; KS-5047; 1,3-Benzenediol, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-; NCGC00017352-14; HSDB 7571; NCGC00024003-08; 533C1DA0-4104-42B5-9D32-9265F40857E4; RM-1812; REGID_for_CID_6240; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; BIK9013; NCGC00257465-01; GTPL8741; BG00606847; NCGC00261796-01; CHEBI:45713; SR-01000000163; Resveratrol, synthetic; SR-01000000163-9; Prestwick2_000508; N88795; 3,5,4'-Trihydroxy-trans-stilbene; resveratrol; 1,3-Benzenediol, 5-((1Z)-2-(4-hydroxyphenyl)ethenyl)-; cis-3,5,4'-trihydroxystilbene; AIDS025474; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; SPBio_002356; BPBio1_000479; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Spectrum4_001896; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; EU-0101111; ST057251; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; resveratrol ; KBioSS_000454; 1684AH; Spectrum3_001821; STL; CHEBI:36002; SPBio_001513; IDI1_002152; Prestwick1_000508; 05F9DB2A-D7E6-4063-8E5B-F7842CF74A5E; 3,5,4'-Trihydroxystilbene; 3,4',5-trihydroxy stilbene; (Z)-resveratrol; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; trans-3,4′,5-Trihydroxystilbene; 31100-06-8; 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Cis resveratrol; SRT-501; NSC327430; 3,4′,5-Trihydroxy-trans-stilbene; Spectrum_001148; 5-[(1Z)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00024003-04; Prestwick3_000508; NCGC00015894-02; Z-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00017352-03; SCHEMBL1931746; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; BSPBio_003461; Bio2_000877; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1-; 31100-06-8 (DELETED); Z-Resveratrol; UNII-AUA0K06FSB; 501-36-0; C03582; AKOS025395422; KBio2_004196; KBio3_002965; Prestwick0_000508; NSC 327430; 34092_RIEDEL; KBio3_000848; NCGC00017352-02; Spectrum5_000552; MolPort-003-850-143; NCGC00024003-06; KBio2_005590; SpecPlus_000391; AC1LU7HY; AUA0K06FSB; KBioGR_000454; AIDS-025474; BSPBio_000435; cis-resveratrol; KBio2_006764; KBio2_001628; KBioGR_002457; CHEMBL87333; 3,4',5-Trihydroxystilbene; Lopac-R-5010; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; KBio2_000454; Resveratrol, (Z)-; SGCUT00007; CJ-13797; NCGC00024003-07; Resveratrol (Z)-form [MI]; NCGC00017352-01; I14-7425; DivK1c_006487; MolMap_000045; 3,4',5-Stilbenetriol; Oprea1_727238; Tocris-1418; DB-072954; NCGC00017352-04; BSPBio_001114; BDBM50131698; 434C671; LUKBXSAWLPMMSZ-UPHRSURJSA-; KBio3_000847; CAS-501-36-0; SMP1_000257; 4q93; MLS000069735; cis-5-[2-(4-Hydroxyphenyl)ethenyl]benzene-1,3-diol; ZINC00006787; (Z)-3,5,4'-trihydroxystilbene; to_000079; SPECTRUM1502223; trans-Resveratrol; R5010_SIGMA; KBio2_003022; 61434-67-1; NCGC00024003-02; NCGC00015894-01; CHEBI:27881; Resveratrol; AC-24235; (E)-resveratrol; Prestwick_619; 5-[2-(4-hydroxyphenyl)vinyl]resorcinol; SMR000058206; TNP00294; Resveratrol, Z-; ZINC12353732; Lopac0_001111; cis-3,4',5-trihydroxystilbene; NCI60_002840; 5-[(E)-2-(4-hydroxyphenyl)vinyl]resorcinol; Bio2_000397; NCGC00024003-00; (Z)-3,4',5-trihydroxystilbene; 3,5-Dihydroxy-4'-methoxystilbene; 3, 5,4'-trihydroxy-trans-stilbene; cis-3,4,5-Trihydroxystilbene; NCGC00024003-08; RM-1812; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; KBioSS_001628; KBio1_001431; 5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; CHEBI:45713; Spectrum2_001497; Prestwick2_000508; 3,5,4'-Trihydroxy-trans-stilbene	C14H12O3	228.24 g/mol	C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O

靶点对应的疾病

疾病ID	疾病名	MeSH名	HPO名	UMLS名	疾病类型

TCMBANKDI000018	Digestive System Diseases; Neoplasms; Endocrine System Diseases	Abnormality of the digestive system; Neoplasm	Neoplastic Process	disease
TCMBANKDI000049	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases	-	Disease or Syndrome	disease
TCMBANKDI000054	Nervous System Diseases; Mental Disorders	Abnormality of the nervous system	Disease or Syndrome	disease
TCMBANKDI000061	Digestive System Diseases; Neoplasms	Abnormality of the digestive system; Neoplasm	Neoplastic Process	group
TCMBANKDI000076	Neoplasms	-	Neoplastic Process	group
TCMBANKDI000166	-	-	Neoplastic Process	disease
TCMBANKDI000402	Skin and Connective Tissue Diseases	-	Disease or Syndrome	disease
TCMBANKDI000891	Neoplasms; Respiratory Tract Diseases	Neoplasm; Abnormality of the respiratory system	Neoplastic Process	disease
TCMBANKDI001597	-	Abnormality of the integument; Abnormality of head or neck; Abnormality of connective tissue	Finding	phenotype
TCMBANKDI002074	Pathological Conditions, Signs and Symptoms; Digestive System Diseases	-	Disease or Syndrome	disease
TCMBANKDI002231	Digestive System Diseases	Abnormality of the digestive system	Disease or Syndrome	disease
TCMBANKDI003353	Pathological Conditions, Signs and Symptoms; Neoplasms	-	Neoplastic Process	phenotype
TCMBANKDI004208	Neoplasms	Neoplasm; Abnormality of the breast	Neoplastic Process	disease
TCMBANKDI004983	Neoplasms; Female Urogenital Diseases and Pregnancy Complications	-	Neoplastic Process	disease
TCMBANKDI005846	Nervous System Diseases; Mental Disorders	-	Disease or Syndrome	disease
TCMBANKDI006055	Pathological Conditions, Signs and Symptoms; Neoplasms	-	Neoplastic Process	disease
TCMBANKDI006612	Neoplasms; Female Urogenital Diseases and Pregnancy Complications	Abnormality of the genitourinary system; Neoplasm	Neoplastic Process	disease
TCMBANKDI006835	-	Abnormality of head or neck	Congenital Abnormality	disease
TCMBANKDI007598	-	Abnormality of the integument	Finding	phenotype
TCMBANKDI009080	Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases	Abnormality of the integument; Abnormality of head or neck	Disease or Syndrome	disease
TCMBANKDI009402	Neoplasms	-	Neoplastic Process	disease
TCMBANKDI009820	Neoplasms; Stomatognathic Diseases	-	Neoplastic Process	disease
TCMBANKDI010048	Infections; Respiratory Tract Diseases	Abnormality of the immune system; Abnormality of the respiratory system	Disease or Syndrome	disease
TCMBANKDI010214	-	-	Neoplastic Process	disease
TCMBANKDI010589	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin and Connective Tissue Diseases	Abnormality of the integument	Disease or Syndrome	disease
TCMBANKDI011173	Neoplasms	-	Neoplastic Process	disease
TCMBANKDI011743	Neoplasms; Skin and Connective Tissue Diseases	Neoplasm; Abnormality of the breast	Neoplastic Process	group
TCMBANKDI012506	Neoplasms	-	Neoplastic Process	disease
TCMBANKDI013628	Neoplasms; Skin and Connective Tissue Diseases	-	Neoplastic Process	disease
TCMBANKDI015452	Neoplasms; Endocrine System Diseases	Abnormality of the endocrine system; Neoplasm	Neoplastic Process	disease
TCMBANKDI015485	Mental Disorders	Abnormality of the nervous system	Mental or Behavioral Dysfunction	disease
TCMBANKDI016026	Neoplasms; Eye Diseases	Neoplasm; Abnormality of the eye	Neoplastic Process	disease
TCMBANKDI016511	Mental Disorders	-	Mental or Behavioral Dysfunction	group
TCMBANKDI017024	Neoplasms; Respiratory Tract Diseases	-	Neoplastic Process	disease
TCMBANKDI017295	-	Abnormality of the integument	Finding	phenotype
TCMBANKDI017642	Neoplasms	Abnormality of the integument; Neoplasm	Neoplastic Process	disease
TCMBANKDI018680	Eye Diseases; Immune System Diseases; Endocrine System Diseases	Abnormality of the endocrine system	Disease or Syndrome	disease
TCMBANKDI019879	Digestive System Diseases; Neoplasms; Endocrine System Diseases	-	Neoplastic Process	disease
TCMBANKDI020912	Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases	-	Disease or Syndrome	disease
TCMBANKDI021472	Pathological Conditions, Signs and Symptoms; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Digestive System Diseases; Skin and Connective Tissue Diseases; Hemic and Lymphatic Diseases	-	Disease or Syndrome	disease
TCMBANKDI023140	Neoplasms; Endocrine System Diseases	Abnormality of the endocrine system; Neoplasm	Neoplastic Process	disease
TCMBANKDI024535	Neoplasms; Respiratory Tract Diseases	Neoplasm; Abnormality of the respiratory system	Neoplastic Process	disease
TCMBANKDI025141	Endocrine System Diseases	Abnormality of the endocrine system; Abnormality of the immune system	Disease or Syndrome	disease
TCMBANKDI025420	Digestive System Diseases; Neoplasms	Abnormality of the digestive system; Neoplasm	Neoplastic Process	disease
TCMBANKDI025917	Neoplasms; Hemic and Lymphatic Diseases	-	Neoplastic Process	disease
TCMBANKDI026459	Neoplasms; Respiratory Tract Diseases; Otorhinolaryngologic Diseases	Neoplasm; Abnormality of the respiratory system	Neoplastic Process	disease
TCMBANKDI027026	Neoplasms; Skin and Connective Tissue Diseases	-	Neoplastic Process	disease
TCMBANKDI027682	Digestive System Diseases; Neoplasms	Abnormality of the digestive system; Neoplasm	Neoplastic Process	disease
TCMBANKDI027825	Neoplasms; Nervous System Diseases	-	Neoplastic Process	disease
TCMBANKDI030204	-	-	Neoplastic Process	disease
TCMBANKDI030540	Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases	Abnormality of the genitourinary system; Neoplasm	Neoplastic Process	disease
TCMBANKDI031189	Neoplasms	Neoplasm; Abnormality of the respiratory system	Neoplastic Process	disease
TCMBANKDI031417	Skin and Connective Tissue Diseases	Abnormality of the integument	Sign or Symptom	phenotype
TCMBANKDI031651	Digestive System Diseases; Neoplasms	-	Neoplastic Process	disease
TCMBANKDI032472	Pathological Conditions, Signs and Symptoms; Neoplasms; Nervous System Diseases	-	Neoplastic Process	disease